Agios Pharmaceuticals, Inc. (AGIO) CEO Jacqualyn Fouse on Q2 2021 Results - Earnings Call Transcript

SA Transcripts
153.96K Followers

Q2: 2021-07-29 Earnings Summary

EPS of -$1.41 misses by $0.11
 | Revenue of $0.00 misses by $2.26M

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q2 2021 Earnings Conference Call July 29, 2021 8:00 AM ET

Company Participants

Jessica Rennekamp - Director, Corporate Communications
Jacqualyn Fouse - Chief Executive Officer
Chris Bowden - Chief Medical Officer
Darrin Miles - Chief Commercial Officer
Jonathan Biller - Chief Financial Officer & Head of Legal and Corporate Affairs

Conference Call Participants

Alethia Young - Cantor Fitzgerald
Kennen MacKay - RBC Capital Markets
Anupam Rama - JPMorgan
Elizabeth Webster - Goldman Sachs
Kelsey Goodwin - Guggenheim Securities
Mark Breidenbach - Oppenheimer
Danielle Brill - Raymond James

Operator

Good morning and welcome to Agios' Second Quarter 2021 Conference Call. At this time all participants are in a listen-only mode. There will be a question-and-answer session at the end. Please be advised that this call is being recorded at Agios' request.

I would now like to turn the call over to Jessica Rennekamp, Director of Corporate Communications.

Jessica Rennekamp

Thank you, operator. Good morning, everyone, and welcome to Agios' second quarter 2021 conference call. You can access Slides for today's call by going to the investors section of our website agios.com.

With me on the call today with prepared remarks are Dr. Jackie Fouse, our Chief Executive Officer; Dr. Chris Bowden, our Chief Medical Officer; Darrin Miles, our Chief Commercial Officer; Jonathan Biller, our Chief Financial Officer and Head of Legal and Corporate Affairs; and Dr. Bruce Car, our Chief Scientific Officer, who will join for Q&A.

Before we get started, I would like to remind everyone that some of the statements we make on this call will include forward-looking statements. Actual events and results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties, and other factors including those set forth in our most recent filings with the SEC and any

Recommended For You

About AGIO Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on AGIO